Pub Date : 2024-05-09DOI: 10.1038/s41429-024-00735-1
Young-Hee Kim, Dae-Cheol Choi, Dae-Won Ki, Yeong-Seon Won, Seung-Jae Lee, Ji-Yul Kim, In-Kyoung Lee, Bong-Sik Yun
Three new nonenes, verrucanonenes A‒C (1‒3), were isolated from culture broth of marine-derived fungus Albifimbria verrucaria. These compounds were isolated using silica gel column chromatography, reversed-phase medium pressure liquid chromatography, Sephadex LH-20 column chromatography, and preparative HPLC. Their structures were determined using a spectroscopic method. Cytotoxicities of these isolated compounds to A549, DU145, HCT116, and HT1080 cancer cell lines were assessed. Compounds 1‒3 exhibited cytotoxicities to DU145 cancer cell line, with IC50 values of 23.4, 28.6, and 20.1 µM, respectively. Compound 2 decreased H1N1-induced cytopathic effects on MDCK cells in a dose-dependent manner.
{"title":"Three new nonenes from culture broth of marine-derived fungus Albifimbria verrucaria and their cytotoxic and anti-viral activities","authors":"Young-Hee Kim, Dae-Cheol Choi, Dae-Won Ki, Yeong-Seon Won, Seung-Jae Lee, Ji-Yul Kim, In-Kyoung Lee, Bong-Sik Yun","doi":"10.1038/s41429-024-00735-1","DOIUrl":"10.1038/s41429-024-00735-1","url":null,"abstract":"Three new nonenes, verrucanonenes A‒C (1‒3), were isolated from culture broth of marine-derived fungus Albifimbria verrucaria. These compounds were isolated using silica gel column chromatography, reversed-phase medium pressure liquid chromatography, Sephadex LH-20 column chromatography, and preparative HPLC. Their structures were determined using a spectroscopic method. Cytotoxicities of these isolated compounds to A549, DU145, HCT116, and HT1080 cancer cell lines were assessed. Compounds 1‒3 exhibited cytotoxicities to DU145 cancer cell line, with IC50 values of 23.4, 28.6, and 20.1 µM, respectively. Compound 2 decreased H1N1-induced cytopathic effects on MDCK cells in a dose-dependent manner.","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":"77 7","pages":"466-470"},"PeriodicalIF":2.1,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140900356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-09DOI: 10.1038/s41429-024-00730-6
Maryam Shafaati, Mohammadreza Salehi, Maryam Zare
Antimicrobial resistance (AMR) is one of the global health challenges of the 21st century that is faced with the twin threats of global climate change and greater longevity, which pose a synergistic risk to the management of AMR. Antimicrobial agents are in high demand due to the challenges faced by increasing life expectancy and the dynamic changes in disease ecology prompted by climate change. In light of global aging and climate change, the complexity and importance of addressing antibiotic resistance are further highlighted by this interplay of issues.
{"title":"The twin challenges of longevity and climate change in controlling antimicrobial resistance","authors":"Maryam Shafaati, Mohammadreza Salehi, Maryam Zare","doi":"10.1038/s41429-024-00730-6","DOIUrl":"10.1038/s41429-024-00730-6","url":null,"abstract":"Antimicrobial resistance (AMR) is one of the global health challenges of the 21st century that is faced with the twin threats of global climate change and greater longevity, which pose a synergistic risk to the management of AMR. Antimicrobial agents are in high demand due to the challenges faced by increasing life expectancy and the dynamic changes in disease ecology prompted by climate change. In light of global aging and climate change, the complexity and importance of addressing antibiotic resistance are further highlighted by this interplay of issues.","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":"77 7","pages":"399-402"},"PeriodicalIF":2.1,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41429-024-00730-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140900354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-08DOI: 10.1038/s41429-024-00734-2
Alicja Sękowska
Plazomicin is a new aminoglycoside with broad-spectrum activity against multidrug-resistant strains. The aim of this study was to assess the susceptibility of the K. pneumoniae strains to plazomicin and other aminoglycosides. The activity of plazomicin in combination with ceftazidim-avibactam or meropenem with selected strains was evaluated. The study involved 60 ESβL-positive K. pneumoniae isolates and 50 carbapenemase-positive. The susceptibility to aminoglycosides was tested using the gradient strip. The in vitro activities of plazomicin and ceftazidim-avibactam or meropenem were evaluated using the MTSTM cross synergy method. Plazomicin exhibited high activity against K. pneumoniae with MICs ranging from 0.19 to 4 µg ml−1 for ESβL-positive strains and from 0.25 to 256 µg ml−1 for carbapenemase-positive strains. No antagonism was identified with any combinations. Plazomicin demonstrated excellent in vitro activity against analyzed strains, suggesting that this antibiotic may be an effective therapeutic option in the treatment of infections caused by MDR K. pneumoniae strains.
{"title":"In vitro activity of plazomicin and other aminoglycosides against Klebsiella pneumoniae multidrug-resistant strains","authors":"Alicja Sękowska","doi":"10.1038/s41429-024-00734-2","DOIUrl":"10.1038/s41429-024-00734-2","url":null,"abstract":"Plazomicin is a new aminoglycoside with broad-spectrum activity against multidrug-resistant strains. The aim of this study was to assess the susceptibility of the K. pneumoniae strains to plazomicin and other aminoglycosides. The activity of plazomicin in combination with ceftazidim-avibactam or meropenem with selected strains was evaluated. The study involved 60 ESβL-positive K. pneumoniae isolates and 50 carbapenemase-positive. The susceptibility to aminoglycosides was tested using the gradient strip. The in vitro activities of plazomicin and ceftazidim-avibactam or meropenem were evaluated using the MTSTM cross synergy method. Plazomicin exhibited high activity against K. pneumoniae with MICs ranging from 0.19 to 4 µg ml−1 for ESβL-positive strains and from 0.25 to 256 µg ml−1 for carbapenemase-positive strains. No antagonism was identified with any combinations. Plazomicin demonstrated excellent in vitro activity against analyzed strains, suggesting that this antibiotic may be an effective therapeutic option in the treatment of infections caused by MDR K. pneumoniae strains.","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":"77 8","pages":"548-551"},"PeriodicalIF":2.1,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140885240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-08DOI: 10.1038/s41429-024-00724-4
Akiho Yagi, Mayu Fujiwara, Mayu Sato, Yuzu Abe, Ryuji Uchida
Three new liposidomycin congeners (1, 2, and 4), together with 14 known liposidomycins (3 and 5–17), were isolated from the culture broth of Streptomyces sp. TMPU-20A065 as anti-Mycobacterium avium complex agents. The structures of liposidomycins were elucidated by spectroscopic analyses, including NMR and MS. Compounds 1, 2, and 4 belong to type-I liposidomycin-containing sulfate groups and methylglutaric acid, each with a different acyl side chain in the structure. Compounds 1–17 exhibited in vitro anti-M. avium and M. intracellulare activities with MIC values ranging between 2.0 and 64 μg ml−1. Furthermore, 1–17 exerted potent therapeutic effects in an in vivo-mimic silkworm infection model with ED50 values ranging between 0.12 and 3.7 μg larva−1 g−1.
{"title":"New liposidomycin congeners produced by Streptomyces sp. TMPU-20A065, anti-Mycobacterium avium complex agents with therapeutic efficacy in a silkworm infection model","authors":"Akiho Yagi, Mayu Fujiwara, Mayu Sato, Yuzu Abe, Ryuji Uchida","doi":"10.1038/s41429-024-00724-4","DOIUrl":"10.1038/s41429-024-00724-4","url":null,"abstract":"Three new liposidomycin congeners (1, 2, and 4), together with 14 known liposidomycins (3 and 5–17), were isolated from the culture broth of Streptomyces sp. TMPU-20A065 as anti-Mycobacterium avium complex agents. The structures of liposidomycins were elucidated by spectroscopic analyses, including NMR and MS. Compounds 1, 2, and 4 belong to type-I liposidomycin-containing sulfate groups and methylglutaric acid, each with a different acyl side chain in the structure. Compounds 1–17 exhibited in vitro anti-M. avium and M. intracellulare activities with MIC values ranging between 2.0 and 64 μg ml−1. Furthermore, 1–17 exerted potent therapeutic effects in an in vivo-mimic silkworm infection model with ED50 values ranging between 0.12 and 3.7 μg larva−1 g−1.","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":"77 7","pages":"412-421"},"PeriodicalIF":2.1,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41429-024-00724-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140885014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Benastatin K (1), a new chlorinated benastatin derivative, was isolated from the culture broth of the actinomycete Streptomyces sp. HGTA384. The structure of 1 was determined on the basis of spectroscopic analysis, including 1D and 2D NMR, as well as HRESI-MS, UV and IR, and comparison with data reported in the literature. Compound 1 and benastatins A and B exhibited inhibitory activity against Micrococcus luteus (MIC 7.8, 31.3, and 3.9 μM, respectively), and IgE-mediated β-hexosaminidase release in RBL-2H3 cells with IC50 values of 42, 79, and 19 μM, respectively.
{"title":"Benastatin K, a chlorinated benastatin-related antibiotic from Streptomyces sp. HGTA384","authors":"Teppei Kawahara, Kanako Saita, Rika Iwamoto, Mikiyo Wada","doi":"10.1038/s41429-024-00727-1","DOIUrl":"10.1038/s41429-024-00727-1","url":null,"abstract":"Benastatin K (1), a new chlorinated benastatin derivative, was isolated from the culture broth of the actinomycete Streptomyces sp. HGTA384. The structure of 1 was determined on the basis of spectroscopic analysis, including 1D and 2D NMR, as well as HRESI-MS, UV and IR, and comparison with data reported in the literature. Compound 1 and benastatins A and B exhibited inhibitory activity against Micrococcus luteus (MIC 7.8, 31.3, and 3.9 μM, respectively), and IgE-mediated β-hexosaminidase release in RBL-2H3 cells with IC50 values of 42, 79, and 19 μM, respectively.","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":"77 7","pages":"471-474"},"PeriodicalIF":2.1,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140658502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-17DOI: 10.1038/s41429-024-00723-5
T. S. Suryanarayanan
There are a limited number of new antibiotics to manage the health crisis caused by the evolution and spread of antimicrobial resistant (AMR) bacteria including multidrug resistant (MDR), extensively drug-resistant (XDR) and pan-drug-resistant (PDR) ones. Bioprospecting fungi of less studied and extreme environments using new and less used older approaches could reveal novel antibiotics to manage MDR pathogens. Furthermore, I posit a crowdsourcing model which could substantially increase the chances of discovering novel antibiotics as well as new chemotypes for other therapeutic areas and considerably reduce the cost and time of this exercise.
{"title":"Crowdsourcing for mining new fungal sources for addressing the need for novel antibiotics against multidrug resistant pathogens","authors":"T. S. Suryanarayanan","doi":"10.1038/s41429-024-00723-5","DOIUrl":"10.1038/s41429-024-00723-5","url":null,"abstract":"There are a limited number of new antibiotics to manage the health crisis caused by the evolution and spread of antimicrobial resistant (AMR) bacteria including multidrug resistant (MDR), extensively drug-resistant (XDR) and pan-drug-resistant (PDR) ones. Bioprospecting fungi of less studied and extreme environments using new and less used older approaches could reveal novel antibiotics to manage MDR pathogens. Furthermore, I posit a crowdsourcing model which could substantially increase the chances of discovering novel antibiotics as well as new chemotypes for other therapeutic areas and considerably reduce the cost and time of this exercise.","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":"77 6","pages":"335-337"},"PeriodicalIF":3.3,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41429-024-00723-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140613661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A new polycyclic tetramate macrolactam designated allostreptamide (1), together with four known congeners, were isolated from the culture extract of Allostreptomyces RD068384. The planar structure of the new compound was elucidated through interpretation of NMR and MS data. The absolute configuration was determined through ROESY and ECD analyses. The isolated compounds revealed antifungal potential against fourteen Candida albicans isolates with minimum inhibitory concentrations (MICs) ranging from 64 to 2048 µg ml-1. Compound 3 showed antibiofilm action and considerably reduced the viability of five isolates (36%) in the formed biofilm. The qRT-PCR revealed that 3 downregulated the BCR1, PLB2, ALS1, and SAP5 biofilm related gene expression. Therefore, 3 could be a promising antifungal therapy for C. albicans infections.
{"title":"A new polycyclic tetramate macrolactam from Allostreptomyces RD068384: stereochemistry and antifungal potential","authors":"Marwa Elsbaey, Yuki Samaru, Engy Elekhnawy, Naoya Oku, Yasuhiro Igarashi","doi":"10.1038/s41429-024-00705-7","DOIUrl":"10.1038/s41429-024-00705-7","url":null,"abstract":"A new polycyclic tetramate macrolactam designated allostreptamide (1), together with four known congeners, were isolated from the culture extract of Allostreptomyces RD068384. The planar structure of the new compound was elucidated through interpretation of NMR and MS data. The absolute configuration was determined through ROESY and ECD analyses. The isolated compounds revealed antifungal potential against fourteen Candida albicans isolates with minimum inhibitory concentrations (MICs) ranging from 64 to 2048 µg ml-1. Compound 3 showed antibiofilm action and considerably reduced the viability of five isolates (36%) in the formed biofilm. The qRT-PCR revealed that 3 downregulated the BCR1, PLB2, ALS1, and SAP5 biofilm related gene expression. Therefore, 3 could be a promising antifungal therapy for C. albicans infections.","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":"77 6","pages":"393-396"},"PeriodicalIF":3.3,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140573028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
During our screening for anti-mycobacterial agents against Mycobacterium avium complex (MAC), two new polycyclic tetramate macrolactams (PTMs), named hydroxycapsimycin (1) and brokamycin (2), were isolated along with the known PTM, ikarugamycin (3), from the culture broth of marine-derived Streptomyces sp. KKMA-0239. The relative structures of 1 and 2 were elucidated by spectroscopic data analyses, including 1D and 2D NMR. Furthermore, the absolute configuration of 1 was confirmed by a single-crystal X-ray diffraction analysis. Compounds 2 and 3 exhibited moderate antimycobacterial activities against MAC, including clinically isolated drug-resistant M. avium.
{"title":"New polycyclic tetramate macrolactams with antimycobacterial activity produced by marine-derived Streptomyces sp. KKMA-0239","authors":"Satoru Shigeno, Miyu Kadowaki, Kenichiro Nagai, Kanji Hosoda, Takeshi Terahara, Tomoyasu Nishimura, Naoki Hasegawa, Hiroshi Tomoda, Taichi Ohshiro","doi":"10.1038/s41429-024-00710-w","DOIUrl":"10.1038/s41429-024-00710-w","url":null,"abstract":"During our screening for anti-mycobacterial agents against Mycobacterium avium complex (MAC), two new polycyclic tetramate macrolactams (PTMs), named hydroxycapsimycin (1) and brokamycin (2), were isolated along with the known PTM, ikarugamycin (3), from the culture broth of marine-derived Streptomyces sp. KKMA-0239. The relative structures of 1 and 2 were elucidated by spectroscopic data analyses, including 1D and 2D NMR. Furthermore, the absolute configuration of 1 was confirmed by a single-crystal X-ray diffraction analysis. Compounds 2 and 3 exhibited moderate antimycobacterial activities against MAC, including clinically isolated drug-resistant M. avium.","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":"77 5","pages":"265-271"},"PeriodicalIF":3.3,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140295411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Strain Odt1-22T, an insect-derived actinomycete was isolated from a termite (Odontotermes formosanus) that was collected from Chanthaburi province, Thailand. Strain Odt1-22T was aerobic, Gram-stain-positive, and produced bud-like spore chain on the substrate hypha. According to chemotaxonomic analysis, strain Odt1-22T contained meso-diaminopimelic acid in peptidoglycan and the whole-cell hydrolysates contained arabinose, galactose, glucose, and ribose. The major menaquinone was MK-8(H4). The diagnostic phospholipids were diphosphatidylglycerol, hydroxyphosphatidylethanolamine, phosphatidylethanolamine and phosphatidylglycerol. Phylogenetic analysis based on 16 S rRNA gene sequence revealed that strain Odt1-22T was identified to the genus Actinomycetospora and showed high similarity values with A. chiangmaiensis DSM 45062 T (99.24%), A. soli SF1T (99.24%) and A. corticicola 014-5 T (98.17%). The genomic size of strain Odt1-22T was 6.6 Mbp with 73.8% G + C content and 6355 coding sequences (CDSs). The genomic analysis, strain Odt1-22T and closely related species A. chiangmaiensis DSM 45062 T, A. soli SF1T and A. corticicola DSM 45772 T displayed the values of average nucleotide identity-blast (ANIb) at 83.7–84.1% and MUMmer (ANIm) at 86.6–87.0%. Moreover, the results of digital DNA-DNA hybridization values between strain Odt1-22T and related Actinomycetospora species were 45.8−50.5% that lower than the threshold value of commonly used to delineate separated species level. On the basis of phenotypic, chemotaxonomic, and genotypic data, strain Odt1-22T represented a novel species within the genus Actinomycetospora, for which the name Actinomycetospora termitidis sp. nov. is proposed. The type strain of the species is Odt1-22T (= TBRC 16192 T = NBRC 115965 T).
从泰国尖竹汶府采集的白蚁（Odontotermes formosanus）中分离出了昆虫放线菌株 Odt1-22T。菌株 Odt1-22T 需氧，革兰氏染色阳性，在基质菌丝上产生芽状孢子链。根据化学分类学分析，菌株 Odt1-22T 的肽聚糖中含有中二氨基亚硒酸，全细胞水解物中含有阿拉伯糖、半乳糖、葡萄糖和核糖。主要的脑醌是 MK-8（H4）。诊断性磷脂是二磷脂酰甘油、羟基磷脂酰乙醇胺、磷脂酰乙醇胺和磷脂酰甘油。基于 16 S rRNA 基因序列的系统进化分析表明，菌株 Odt1-22T 被鉴定为放线菌属，与 A. chiangmaiensis DSM 45062 T（99.24%）、A. soli SF1T（99.24%）和 A. corticicola 014-5 T（98.17%）具有很高的相似度。菌株 Odt1-22T 的基因组大小为 6.6 Mbp，G + C 含量为 73.8%，编码序列（CDS）为 6355 个。经基因组分析，菌株 Odt1-22T 与近缘种 A. chiangmaiensis DSM 45062 T、A. soli SF1T 和 A. corticicola DSM 45772 T 的平均核苷酸同一性 Blast (ANIb) 值为 83.7-84.1%，MUMmer (ANIm) 值为 86.6-87.0%。此外，Odt1-22T菌株与相关放线菌之间的数字DNA-DNA杂交值为45.8%-50.5%，低于通常用于划分分离物种水平的阈值。根据表型学、化学分类学和基因型数据，菌株 Odt1-22T 代表了放线菌属中的一个新种，拟命名为白蚁放线菌 sp.nov.。该物种的模式菌株为 Odt1-22T（= TBRC 16192 T = NBRC 115965 T）。
{"title":"Actinomycetospora termitidis sp. nov., an insect-derived actinomycete isolated from termite (Odontotermes formosanus)","authors":"Khomsan Supong, Nantawan Niemhom, Chanwit Suriyachadkun, Wongsakorn Phongsopitanun, Somboon Tanasupawat, Pattama Pittayakhajonwut","doi":"10.1038/s41429-024-00712-8","DOIUrl":"10.1038/s41429-024-00712-8","url":null,"abstract":"Strain Odt1-22T, an insect-derived actinomycete was isolated from a termite (Odontotermes formosanus) that was collected from Chanthaburi province, Thailand. Strain Odt1-22T was aerobic, Gram-stain-positive, and produced bud-like spore chain on the substrate hypha. According to chemotaxonomic analysis, strain Odt1-22T contained meso-diaminopimelic acid in peptidoglycan and the whole-cell hydrolysates contained arabinose, galactose, glucose, and ribose. The major menaquinone was MK-8(H4). The diagnostic phospholipids were diphosphatidylglycerol, hydroxyphosphatidylethanolamine, phosphatidylethanolamine and phosphatidylglycerol. Phylogenetic analysis based on 16 S rRNA gene sequence revealed that strain Odt1-22T was identified to the genus Actinomycetospora and showed high similarity values with A. chiangmaiensis DSM 45062 T (99.24%), A. soli SF1T (99.24%) and A. corticicola 014-5 T (98.17%). The genomic size of strain Odt1-22T was 6.6 Mbp with 73.8% G + C content and 6355 coding sequences (CDSs). The genomic analysis, strain Odt1-22T and closely related species A. chiangmaiensis DSM 45062 T, A. soli SF1T and A. corticicola DSM 45772 T displayed the values of average nucleotide identity-blast (ANIb) at 83.7–84.1% and MUMmer (ANIm) at 86.6–87.0%. Moreover, the results of digital DNA-DNA hybridization values between strain Odt1-22T and related Actinomycetospora species were 45.8−50.5% that lower than the threshold value of commonly used to delineate separated species level. On the basis of phenotypic, chemotaxonomic, and genotypic data, strain Odt1-22T represented a novel species within the genus Actinomycetospora, for which the name Actinomycetospora termitidis sp. nov. is proposed. The type strain of the species is Odt1-22T (= TBRC 16192 T = NBRC 115965 T).","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":"77 5","pages":"299-305"},"PeriodicalIF":3.3,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140289625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：